Skip to search boxSkip to navigationSkip to main content

A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India

  • Indumathi Manoharan
    ,
  • Rathnam Boopathy
    ,
  • Sultan Darvesh
    ,
  • Oksana Lockridge(corresponding author)
*Corresponding author for this work
  • Bharathiar University
    ,
  • QEII Health Sciences Centre
    ,
  • University of Nebraska Medical Center
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Background: Butyrylcholinesterase (BChE; gi:116353) deficiency has adverse effects on the response to succinylcholine and mivacurium. A physiological function of BChE is to inactivate octanoyl ghrelin. We determined the health effect of complete absence of BChE in humans. Methods: Clinical tests of cardiac, lung, liver, and kidney function, body weight, sperm counts and motility were performed on 5 men, age 20-32 y, in the Vysya community of Coimbatore, India who had silent BChE. Postmortem tissues from 2 cadavers with wild-type BChE were assayed. Results: Test results were normal, except for lung function, which indicated mild obstruction in silent as well as in wild-type BChE subjects. Creatine kinase-MB levels were high in 2 subjects, but there were no other indications of damage to the heart. Body weight was normal. Family histories revealed no trend in disease susceptibility. The human body contains 10 times more BChE than acetylcholinesterase molecules. Conclusion: Individuals completely deficient in BChE have only minor abnormalities in clinical test results. However, they respond abnormally to standard doses of succinylcholine and mivacurium. It is expected, but not proven, that they are unusually susceptible to the toxicity of cocaine and organophosphorus pesticides, and resistant to bambuterol and irinotecan. Their normal body weight suggests alternative routes for deactivation of octanoyl ghrelin.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 128-135 (8 pages)

Journal (Volume, Issue Number)

Clinica Chimica Acta (Volume 378, Issue 1-2)

Publication milestones

  • Published - 03/2007

Publication status

Published - 03/2007

ISSN

0009-8981

Publication IDs

  • Scopus: 33846969163
  • PubMed: 17182021

Publication metrics

Metrics

Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
citations
78
SciVal
FWCI
1.20
SciVal
Author count
4
SciVal
Paper percentile
93
SciVal
Top percentile
10

PlumX, opens in new tab

Citation count
111
Captures
80

Funding Details

This work was supported by the Indian funding agency, AICTE, New Delhi Grant F. No 8019/RDII/BOR/R&D 226/2001 (to RB), IM was funded by a Research Fellowship from Bharathiar University, contracts W81XWH-06–1-0102 and W911SR-04-C-0019 from the US Department of Defense (to OL), the Canadian Institutes of Health Research, Nova Scotia Health Research Foundation, Capital District Health Authority Research Fund, Heart and Stroke Foundation of Nova Scotia, Canada and the Brain Tumour Foundation of Canada (to SD).
FundersFunding numbers
Capital District Health Authority Research Fund, Heart and Stroke Foundation of Nova Scotia
-
DOD
-
CIHR
-
NSHRF
-
Brain Tumour Foundation of Canada
-
अभातशिप
8019/RDII/BOR/R&D 226/2001
Bharathiar University
W81XWH-06–1-0102, W911SR-04-C-0019